New opportunities in the treatment of type 2 diabetes mellitus in patients with cardiovascular diseases: innovations in pharmacotherapy and revision of clinical guidelines
Vestnik of Saint Petersburg University. Medicine · 2025 · 20 (1) · 4-18
DOI: 10.21638/spbu11.2025.101 ↗Kurz gefasst
Leitlinie in der Zeitschrift Vestnik of Saint Petersburg University. Medicine, 2025. Verfasst von Daria Konovalova und 4 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) is a common chronic disease characterized by impaired carbohydrate metabolism caused by insulin resistance and relative insufficiency of insulin secretion. Approaches to the pharmacotherapy of this condition have undergone significant changes due to the introduction of modern classes of drugs, such as sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors). This article examines contemporary approaches to T2DM pharmacotherapy and describes changes in treatment strategies driven by the adoption of these drug classes. Modern drugs have demonstrated high efficacy in achieving comprehensive glycemic control and reducing the risk of cardiovascular complications. The SGLT2 inhibitor group exhibits a pronounced cardioprotective effect, contributing to a reduction in hospitalization rates for chronic heart failure. The GLP-1 RAs promote weight loss and improve cardiovascular outcomes, while the DPP-4 inhibitors are distinguished by their favorable safety profile, minimizing the risk of hypoglycemia. The article emphasizes the need for cardioprotective agents as second-line therapy and highlights the importance of a multidisciplinary approach. Prospects for further investigation of the long-term effects of these new drug classes are discussed, aiming to develop optimal treatment regimens tailored to the individual characteristics of patients and the stage of the disease.
Zitieren
APA
Konovalova, D., Aleshina, Y., Shabaeva, E., Nedbaylo, S., & Kudriashova, P. (2025). New opportunities in the treatment of type 2 diabetes mellitus in patients with cardiovascular diseases: innovations in pharmacotherapy and revision of clinical guidelines. Vestnik of Saint Petersburg University. Medicine, 20(1), 4-18. https://doi.org/10.21638/spbu11.2025.101
Vancouver
Konovalova D, Aleshina Y, Shabaeva E, Nedbaylo S, Kudriashova P. New opportunities in the treatment of type 2 diabetes mellitus in patients with cardiovascular diseases: innovations in pharmacotherapy and revision of clinical guidelines. Vestnik of Saint Petersburg University. Medicine. 2025;20(1):4-18. doi:10.21638/spbu11.2025.101
BibTeX
@article{Konovalova2025,
author = {Konovalova, Daria and Aleshina, Yuliya and Shabaeva, Elizaveta and Nedbaylo, Sofia and Kudriashova, Polina},
title = {New opportunities in the treatment of type 2 diabetes mellitus in patients with cardiovascular diseases: innovations in pharmacotherapy and revision of clinical guidelines},
journal = {Vestnik of Saint Petersburg University. Medicine},
year = {2025},
volume = {20},
number = {1},
pages = {4--18},
doi = {10.21638/spbu11.2025.101}
}
EUVIMED